Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$2.0 million.

  • C4 Therapeutics' Change in Accured Expenses fell 14829.82% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year decrease of 680500.0%. This contributed to the annual value of -$1.3 million for FY2024, which is 19627.66% down from last year.
  • As of Q3 2025, C4 Therapeutics' Change in Accured Expenses stood at -$2.0 million, which was down 14829.82% from $627000.0 recorded in Q2 2025.
  • C4 Therapeutics' 5-year Change in Accured Expenses high stood at $5.2 million for Q4 2023, and its period low was -$7.7 million during Q1 2024.
  • Its 5-year average for Change in Accured Expenses is $73210.5, with a median of $627000.0 in 2025.
  • The largest annual percentage gain for C4 Therapeutics' Change in Accured Expenses in the last 5 years was 66916.78% (2024), contrasted with its biggest fall of 42607.08% (2024).
  • Quarter analysis of 5 years shows C4 Therapeutics' Change in Accured Expenses stood at $2.1 million in 2021, then rose by 26.09% to $2.7 million in 2022, then skyrocketed by 92.5% to $5.2 million in 2023, then decreased by 23.29% to $4.0 million in 2024, then tumbled by 150.69% to -$2.0 million in 2025.
  • Its Change in Accured Expenses stands at -$2.0 million for Q3 2025, versus $627000.0 for Q2 2025 and -$6.7 million for Q1 2025.